FDA Alignment Paves Registration Pathway for INmune Bio's Alzheimer's Candidate
Event summary
- INmune Bio received formal FDA minutes confirming alignment on a Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer’s Disease.
- The FDA supports INmune Bio’s enrichment-led trial design, targeting patients with specific inflammatory biomarker profiles.
- CDR-SB will serve as the sole primary efficacy endpoint for the Phase 3 trial, aligning with industry standards.
- The Phase 2b portion will enroll ~300 participants over 9 months, followed by a Phase 3 enrollment of ~1,000 participants over 18 months.
- An exploratory cohort of ~20% of patients will be included to assess broader effects of XPro1595.
The big picture
The FDA’s support for INmune Bio’s precision medicine approach reflects a growing trend towards targeted therapies in Alzheimer’s disease, moving away from broad-spectrum treatments. This validation is critical for INmune Bio, which has been developing XPro1595 as a differentiated treatment based on immune modulation. The reliance on CDR-SB as the primary endpoint also underscores the pressure on Alzheimer’s therapies to demonstrate meaningful clinical benefit, given the recent regulatory scrutiny of therapies with questionable efficacy.
What we're watching
- Execution Risk
- The success of the integrated Phase 2b/3 trial hinges on effectively identifying and enrolling the enriched patient population, which could be challenging given the reliance on multiple biomarkers.
- Regulatory Headwinds
- While the FDA has indicated alignment, the agency's feedback isn't a guarantee of approval, and future interactions could reveal unexpected hurdles or require protocol modifications.
- Commercial Viability
- The inclusion of an exploratory cohort suggests uncertainty about XPro1595's efficacy in a broader patient population, potentially impacting its commercial appeal if the enriched cohort proves essential for success.
Related topics